These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20333747)

  • 1. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation.
    Rayment EA; Williams DJ
    Stem Cells; 2010 May; 28(5):996-1004. PubMed ID: 20333747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
    Yim R
    Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific considerations for the regulatory evaluation of cell therapy products.
    Petricciani J; Hayakawa T; Stacey G; Trouvin JH; Knezevic I
    Biologicals; 2017 Nov; 50():20-26. PubMed ID: 28888427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The translation of cell-based therapies: clinical landscape and manufacturing challenges.
    Heathman TR; Nienow AW; McCall MJ; Coopman K; Kara B; Hewitt CJ
    Regen Med; 2015; 10(1):49-64. PubMed ID: 25562352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.
    Ratcliffe E; Thomas RJ; Williams DJ
    Br Med Bull; 2011; 100():137-55. PubMed ID: 21852279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the potency of a stem cell therapeutic.
    Harper H; Rich IN
    Methods Mol Biol; 2015; 1235():33-48. PubMed ID: 25388384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development.
    Carmen J; Burger SR; McCaman M; Rowley JA
    Regen Med; 2012 Jan; 7(1):85-100. PubMed ID: 22168500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell-based therapies in Parkinson's disease: future hope or current treatment option?
    Loewenbrück K; Storch A
    J Neurol; 2011 May; 258(Suppl 2):S346-53. PubMed ID: 21437664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of Good Manufacturing Practice (GMP) for Biomedical Cell Products.
    Tulina MA; Pyatigorskaya NV
    Bull Exp Biol Med; 2018 Mar; 164(4):579-582. PubMed ID: 29504094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bench-to-bedside translation of stem cell therapies: where are we now and where are we going?
    Martino G
    Regen Med; 2016 Jun; 11(4):347-9. PubMed ID: 27188381
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospects for translational regenerative medicine.
    Chen FM; Zhao YM; Jin Y; Shi S
    Biotechnol Adv; 2012; 30(3):658-72. PubMed ID: 22138411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved harmonization of critical characterization assays across cell therapies.
    Karanu F; Ott L; Webster DA; Stehno-Bittel L
    Regen Med; 2020 May; 15(5):1661-1678. PubMed ID: 32589107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy.
    Aghayan HR; Goodarzi P; Arjmand B
    Methods Mol Biol; 2015; 1283():93-107. PubMed ID: 25138723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
    McGowan NWA; Campbell JDM; Mountford JC
    Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One, two, three steps toward cell therapy for stroke.
    Diamandis T; Borlongan CV
    Stroke; 2015 Feb; 46(2):588-91. PubMed ID: 25503552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cell therapy for Parkinson's disease with induced pluripotent stem cells].
    Morizane A
    Rinsho Shinkeigaku; 2019 Mar; 59(3):119-124. PubMed ID: 30814448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory requirements in the good manufacturing practice production of an epithelial cell graft for ocular surface reconstruction.
    Sheth-Shah R; Vernon AJ; Seetharaman S; Neale MH; Daniels JT
    Regen Med; 2016 Apr; 11(3):307-20. PubMed ID: 26987030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Media fill for validation of a good manufacturing practice-compliant cell production process.
    Serra M; Roseti L; Bassi A
    Methods Mol Biol; 2015; 1283():161-9. PubMed ID: 25096172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating stem cell research from the bench to the clinic: a need for better quality data.
    Plant AL; Parker GC
    Stem Cells Dev; 2013 Sep; 22(18):2457-8. PubMed ID: 23597110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell therapy for chronic heart failure: an updated appraisal.
    Maltais S; Joggerst SJ; Hatzopoulos A; DiSalvo TG; Zhao D; Sung HJ; Wang X; Byrne JG; Naftilan AJ
    Expert Opin Biol Ther; 2013 Apr; 13(4):503-16. PubMed ID: 23289619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.